Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia
Abstract Converging findings have established that the endocannabinoid (eCB) system serves as a possible target for the development of new…
Joshua Levitz
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia
Abstract Converging findings have established that the endocannabinoid (eCB) system serves as a possible target for the development of new…